Therapeutic Drug Monitoring of Vancomycin Concentrations for the Management of Bone and Joint Infections
Vancomycin is used for the treatment of bone and joint infections (BJI), but scarce information is available about its pharmacokinetic/pharmacodynamic (PK/PD) characteristics. We aimed to identify the risk factors associated with the non-achievement of an optimal PK/PD target in the first therapeuti...
| Autores: | , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | inglés |
| OAI Identifier: | oai:ddd.uab.cat:272888 |
| Acceso en línea: | https://ddd.uab.cat/record/272888 https://dx.doi.org/urn:doi:10.3390/tropicalmed8020113 |
| Access Level: | acceso abierto |
| Palabra clave: | Bone and joint infections Vancomycin Therapeutic drug monitoring Pharmacokinetics Nephrotoxicity Dosage regimens |
| Sumario: | Vancomycin is used for the treatment of bone and joint infections (BJI), but scarce information is available about its pharmacokinetic/pharmacodynamic (PK/PD) characteristics. We aimed to identify the risk factors associated with the non-achievement of an optimal PK/PD target in the first therapeutic drug monitoring (TDM). Methods: A retrospective study was conducted in a tertiary hospital from January 2020 to January 2022. Patients with BJI and TDM of vancomycin on day 2 of treatment were included. Initial vancomycin fixed doses (1 g every 8 h or 12 h) was decided by the responsible doctors. According to TDM results, dosage adjustments were performed. An AUC/MIC < 400 mg × h/L, between 400 and 600 mg × h/L and. |
|---|